Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Merger or Acquisition (January 2026)
11 slides from Boston Scientific's merger presentation, Jan 15, 2026
Slide 1: Boston Scientific Announces Agreement to Acquire Penumbra, Inc.
Boston Scientific Announces Agreement to Acquire Penumbra, Inc. January 15, 2026
Slide 2: Safe harbor for forward-looking statements
Safe harbor for forward-looking statements Certain statements that we may make from time to time, including statements contained in this presentation and information incorporated by reference herein, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 193
Slide 3: Important Information and Where to Find It
Important Information and Where to Find It In connection with the proposed transaction, Boston Scientific will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 that will include a proxy statement/prospectus (the “Proxy Statement/Prospectus”) for the s
Slide 4: Today's Presenters
Today’s Presenters Boston Scientific Penumbra MIKE MAHONEY JONATHAN MONSON ADAM ELSESSER Chairman & Chief Executive Officer Executive Vice President & Chairman & Chief Executive Officer Chief Financial Officer 4
Slide 5: Advancing science for life
Our purpose Advancing science for life Caring Meaningful innovation High performance Global collaboration Diversity Winning spirit 5
Slide 6: BSX + PEN: Strong strategic and financial fit
BSX + PEN: Strong strategic and financial fit Announced definitive agreement to acquire Penumbra, valued at $374 per share Entry into new, key segments with a WAMGR accretive to BSX Mechanical thrombectomy, embolization and neurovascular are large, underserved spaces Expands access for more physicia
Slide 7: Penumbra, Inc. Overview
Penumbra, Inc. Overview A leader in vascular solutions focused on developing innovative technologies Financials Headquartered in Products Manufactured Alameda, CA in California Q4 and FY 2025 Preliminary Revenue1 +21.4-22.0% +17.3-17.5% Q4:25 FY:25 Reported growth Reported growth (vs. 2024) (vs. 202
Slide 8: Expanding Into Significant Untapped New Segments
Expanding Into Significant Untapped New Segments Middle Meningeal Stroke Thrombectomy Artery Embolization (MMAe) Embolization and Access Total Annual Pulmonary Coronary Total Annual Embolism (PE) U.S. U.S. Opportunity Opportunity 1,250,000+ 315,000+ Peripheral Arterial Patients Venous / DVT Patients
Slide 9: Penumbra Portfolio and Pipeline
Penumbra Portfolio and Pipeline WAMGR of ~11% in high-growth adjacent areas Embolization & Access Mechanical Thrombectomy ~HSD growth opportunity ~Mid-teens growth opportunity Peripheral Key Products Key Products Ruby® Coil Lightning Flash® 3.0 POD®, Packing Coil Lightning Bolt® 7&12 ~MSD growth opp
Slide 10: Entering a New Phase of Innovation-Fueled Growth
Entering a New Phase of Innovation-Fueled Growth PE / DVT / ALI MMA Stroke Computer Assisted Vacuum Thrombectomy Middle Meningeal Artery (MMA) (CAVT) for Acute Intermediate-High Risk Blood Clot Removal for Ischemic Stroke Embolization for Pulmonary Embolism (PE) & Acute Limb with CAVT Technology Chr
Slide 11: Transaction Details
Transaction Details Expect to complete the transaction in 2026 • Transaction consideration reflects a total equity value of $15B to be funded in approx. $11B in cash and approx. $4B in Boston Scientific stock, resulting in a 73% Transaction Structure cash, 27% stock mix • Based on Boston Scientific’
Boston Scientific — Merger or Acquisition (January 2026) on 6ix